#11 Owens CM &Minor Barclays Global Healthcare Conference March 15, 2022 Confidential & Proprietary to Owens & Minor, Inc. Owens &Minor#2Safe Harbor 2 This presentation contains certain "forward looking" statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the proposed transaction with Apria, Inc. ("Apria") and opportunities related thereto, expectations with respect to our financial performance and related assumptions, the Owens & Minor, Inc.'s ("Owens & Minor" or the "Company") business, the impact of COVID-19 on the Company's results and operations, and the Company's financial targets. Forward looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected, targeted or contemplated in the forward looking statements, including that the proposed transaction will not be completed on a timely basis or at all, whether due to the failure to satisfy the conditions of the related agreement or otherwise, the possibility that stockholders of Apria may not approve the transaction, the risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected and the risk that the combined company may be unable to achieve synergies or that it may take longer than expected to achieve those synergies. Investors should refer to each of Owens & Minor's and Apria's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC, including the sections captioned "Cautionary Note Regarding Forward Looking Statements" and "Item 1A. Risk Factors," and subsequent current reports on Form 8-K filed with the SEC, for a discussion of certain known risk factors that could cause the Company's actual results to differ materially from those projected, targeted or contemplated in the forward looking statements. Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward-looking statements, as a result of new information, future developments or otherwise. This presentation includes certain combined financial information which reflects the sum of the relevant financial information for the Company and Apria without any other adjustments and refer to such presentation as on a "combined" basis for the applicable period. This combination does not comply with U.S. GAAP or with the rules for pro forma presentation. As a result, the combined financial information included in this presentation may differ from pro forma financial information prepared in accordance with U.S. GAAP and the rules and regulations of the SEC, and any such differences could be material. Numerical figures included in this presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. As such, the corresponding percentage aggregations may not sum to 100%. We present certain potential cost savings as an adjustment to Combined Adjusted EBITDA because we expect them to be a permitted addback pursuant to agreements that govern our indebtedness. These potential cost savings are based on assumptions and estimates that could be proved to be incorrect, and accordingly should not be viewed as a projection of future performance. Certain financial measures included herein are not made in accordance with U.S. GAAP and use of such terms varies from others in the same industry. Management uses these non-GAAP financial measures internally to evaluate our performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation. Non-GAAP financial measures should not be considered as alternatives to measures derived in accordance with U.S. GAAP. Non-GAAP financial measures have important limitations as analytical tools and you should not consider them in isolation or as substitutes for results as reported under U.S. GAAP. The appendix to this presentation includes a reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with U.S. GAAP. Owens VI & Minor#33 OMI Overview: Leading Healthcare Solutions Provider A growth-focused, integrated healthcare solutions provider with broad medical distribution reach, proprietary products and services, and a leading home health business that empowers customers to advance healthcare Owens M&Minor 15,000+ Teammates Worldwide 5125 AR Q HO 1,200+ Branded Manufacturers ✓ 140 years of legacy service Large North American manufacturing footprint that helps serve PPE needs Extensive medical distribution platform and network of trusted relationships Supported by value-added services and technology solutions that drive recurring revenue and "sticky" partnerships Portfolio of proprietary products and emerging home health business that we expect will fuel growth Record of strong growth in Patient Direct business since acquiring Byram Healthcare, expected to be enhanced by strategic acquisition of Apria roon -NA 4,000+ Healthcare Providers Served a- 95+ Facilities Worldwide Owens M&Minor#4How Our Businesses Work Together Today DESIGN 4 RAW MATERIALS MEDICAL DISTRIBUTION MANUFACTURING DISTRIBUTION DISTRIBUTION PRODUCTS & HEALTHCARE SERVICES SEGMENT PROPRIETARY PRODUCTS HALYARD MEDICHOICEⓇ M Medical Action ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ INDUSTRIES INC.Ⓡ Owens M&Minor CM 1. Acquisition of Apria is expected to close in the first half of 2022. DELIVERY SERVICES HOSPITAL/IDN QSight SURGITRACKⓇ PANDACSM my Our Value Chain is a Key Differentiator HOME HEALTH PATIENT DIRECT SEGMENT © CHRONIC CARE AT HOME Byram APRIA HEALTHCARE 1 Owens VI & Minor#55 Alternate Care Market Overview Byram and Apria also compete in the Home Health & Hospice market, accounting for an additional $750mm in B2B supply spending² Byram APRIA HEALTHCAR 1 Grandview Research report published August 2021 2 2020 Home Health Agency Report Home Health & Hospice LTC/SNFs / Rehabs / Sub- Acute Care Facilities mHealth/ Remote Monitoring Chronic Care at Home (DME Soft Goods) Medications/ Pharmacy DME (Respiratory Equipment) Cash / Retail Overall DME in 2020:~$50bn 2021 2028 Growth CAGR: 6%¹ - Byram and Apria compete primarily in the soft goods DME market APRIA Byram HEALTHCARE® Apria competes in the cash/retail space with its Apria Direct business *APRIA DIRECT Ability to serve a large and fast-growing sector Owens VI & Minor#66 Byram - A Leader in Fast Growing Home Health Sector Key highlights Direct-to-patient distributor of medical supplies to U.S. patients with chronic diseases ● ● ● ● ● ● Specializes in diabetes, urology, ostomy, wound care, incontinence, and breast pumps In network provider with over 85% of U.S. insured lives covered 650+ Managed Care contracts National footprint, Regional presence Insurance reimbursement and billing expertise Urology / Incontinence / Enteral / Ostomy / Wound Care Spokane, WA I Bothell, WA Everett, WA Portland, OR Huntington Beach, CA Diabetes Salt Lake City, UT Urology / Incontinence Denver, CO Dallas, TX Wound Care / Ostomy Chicago, IL Germantown, TN Birmingham, AL Center of Excellence Reimbursement Center Core Geographic Markets Distribution Center Ann Arbor. MI Sales & Service Center Diabetes/ Urology / Ostomy South Bend,/ IN Byram White Plains, NY 33 Marietta, GA Somerse t, NJ HEALTHCARE® Worcester, MA Home Health Clearwater, FL Owens VI & Minor#77 Apria Builds on OMI's Success in the Patient Direct Segment ● ● Leading provider of integrated home healthcare equipment and related services in the U.S. Offers a comprehensive range of products and services for in-home care and delivery across: Home respiratory ● ● ● Obstructive sleep apnea Negative pressure wound therapy Home medical equipment and other services Geographic Footprint OVER 275 SERVICE LOCATIONS NATIONWIDE HME & Other Services ● Home Respiratory ● Provides home healthcare therapies requiring high-touch service Expertise in fee-for service as well as capitation arrangements -6,500 employees serving approximately 2 million patients annually Product Categories Payor mix 78% commercial, 21% Medicare, 1% Medicaid NPWT Obstructive Sleep Apnea Strong Payor Relationships APRIA KAISER PERMANENTE. Anthem. Cigna Humana aetnaⓇ UnitedHealthcare Owens VI & Minor#8Apria Acquisition - Strategic Rationale Expands Patient Direct Segment and Recurring Revenue Well-positioned across key product categories exposed to strong underlying growth drivers 8 ♫ Expands offerings across chronic and acute conditions, with opportunities to treat overlapping conditions for patients Enhanced geographic reach Payor relationship growth Brings greater efficiency to the home healthcare supply market History of strong performance by the Byram team instills confidence and excitement around Apria acquisition Track record of profitable growth and value creation by Apria team Byram HEALTHCARE Patient Direct Product Lines 0%, Home Respiratory Obstructive Sleep Apnea Negative Pressure Wound Therapy HME & Other Services Diabetes Ostomy Incontinence Traditional Wound Care Urology Breast Pumps main APRIA Approximately 50% of all type 2 diabetics and ~80% of all those with clinically diagnosed obesity experience sleep apnea, a chronic condition. ✓ Significant opportunities for cross-selling of products from Apria and Byram, simplifying the patient, payor, and provider experience Owens M&Minor#9● ■ Adding approximately $1.2 billion of annual net revenue ▪ Adds in excess of $230 million in incremental adjusted EBITDA, implying -20% margin Annualized Financial Impact (Pre-Synergies) ▪ Annual capex requirements of ~$100 million ▪ FCF generation > $80 million Leverage Ratio to increase to just under 4x TTM adjusted EBITDA Expect to return to targeted leverage range of 2-3x within 24 months ■ • No changes to capital allocation priorities Deleverage the balance sheet - Re-invest organically in broader business to drive top-line growth / bottom-line efficiencies 9 Expect to change segment reporting structure beginning with 1Q22 filings - Patient Direct = Byram + Apria Products & Healthcare Services = Global Products + Medical Distribution and Services Transaction will be accretive to EPS in 2022 assuming 1H22 close - Combined Net Revenue ¹ (~$10.9B) 1 Combined numbers are non-GAAP and reflect the summation of OMI plus Apria, for FY 2021. See slide 2 for more information regarding OMI and Apria Combined measures and important limitations Patient Direct -20% Products & Healthcare Services -80% Combined Adjusted EBITDA¹ (~$725M) Products & Healthcare Services ~50% Patient Direct -50% Owens VI & Minor#1010 Owens & Minor (OMI) - Investment Thesis 1 6 Favorable trends driving robust demand 2 One of the market leaders in the fast-growing home health segment 3 4 Vertical integration creates stability and competitive advantage Diverse earnings profile across customers, payors, products and geographies 5 Strong cash flow profile provides ability to significantly reduce debt Experienced management with proven track record of success Owens VI & Minor#111 Favorable Trends Driving Robust Demand 11 Durable Medical Equipment Expenditures: Historic and Projected (CMS) ($bn)¹ 40 2010 42 2011 Aging population Rising incidence of chronic diseases Preference for in-home care 44 2012 Continued shift toward home healthcare Highly fragmented market CAGR 2010-2018: 4.3% 45 2013 47 2014 49 2015 51 2016 52 2017 55 2018 57 2019 55 2020 66 70 CAGR 2019E-2028E: 6.2% 74 78 83 88 2021E 2022E 2023E 2024E 2025E 2026E 2027E Improved technology has increased number of treatments administered at home ■Patients prefer the convenience of in-home care 93 U.S. population aged 65+ will grow substantially from 15.2% to 20.6% of the population between 2016 and 2030 98 Increasing obesity rates and historically high prevalence of smoking will drive diagnosis rates for a number of chronic conditions Certain chronic diseases currently under-diagnosed 2028E Home healthcare increasingly sought out as an attractive, cost-effective and clinically appropriate alternative to facility-based care Pandemic environment further emphasized the need for home healthcare as a low-risk setting Source: CMS, United States Census Bureau, Medicare Payment Advisory Commission, HME News, and Henry J. Kaiser Family Foundation 1 The latest projections were published in 2018 and are shown from 2021 through 2028. These projections do not take into account the impact of COVID-19 because of the timing of the report and the highly uncertain nature of the pandemic. 2019 and 2020 actual results were sourced from CMS. Between 2012 and 2018, the overall number of durable medical equipment, prosthetics, orthotics and supplies suppliers that bill Medicare more than $10mm annually fell from 73 to 57 The market remains highly fragmented and competitive Owens VI & Minor#121 12 Favorable Trends Driving Robust Demand (cont'd) PPE Impact on Global Products Volume Opportunities for growth exist beyond COVID-enhanced levels with the return of elective procedures and demand for PPE in new industries Revised healthcare protocols and new customer stockpiling requirements driving increased use of PPE National demand for stockpile replenishment Increased use of PPE in both healthcare and non-healthcare settings Preference for medical grade PPE by healthcare professionals Customer growth New end markets, including Industrial, Specialty and International Pre-Pandemic PPE Demand Post-Pandemic Peak Surge abates, but normalized levels remain higher due to new healthcare protocols and new markets Market Opportunity is Much Greater Than Pre-Pandemic Owens M&Minor#132 A Market Leader in the Fast-Growing Home Health Sector Patient Direct Market Outlook U.S. Market Size and Growth (Addressable Market) 13 Segment Ostomy Wound Care Urology Diabetes Incontinence Respiratory Devices Obstructive Sleep Apnea Negative Pressure Wound Therapy Market Size ($mm)² 800 635 1,300 3,700 800 6,200 2,200 2,100 1 Represents compound annual growth from 2018 through 2025 Source: Ostomy: 2 Addressable market sizes as of 2020, per management internal estimates WC: Market CAGR ('21-23) 2% 4% 4% 9% 5% 6%1 8%1 5%1 APRIA THCARE Byram Est. CMS Medicare data; UOAA Estimate based on CMS Medicare data and HHA cost report data Urology: iData Research- "Urology Market Size, Share & COVID-19 Impact Analysis" Diabetes: Mordor Intelligence 2019 (45% addressable of total $8B) National Association for Continence Broadening Service Portfolio Inco: Resp. devices: Orion Market Research, "U.S. Respiratory Device Market 2019-2025" Obs. Sleep apnea: The Insight Partners, "North America Sleep Apnea Devices Market" NPWT: Markets and Markets, "Negative Pressure Wound Therapy (NPWT) Market" HME & DME Breast Pumps Ostomy Non-Invasive Ventilation Oxygen Diabetes Urology 11 Sleep NPWT Incontinence Wound Care Owens & Minor#143 Vertical Integration Creates Stability and Competitive Advantage (cont'd) Key Takeaways: OMI controls the design, raw materials, strict quality standards, and product specifications in its own facilities with its own teammates ● Proprietary branded products are self manufactured, many in the Americas 44 distribution centers are strategically located in North America for rapid deployment with ~99.5% on-time deliveries Vertical integration coupled with strategic footprint drives margin and represents an advantage over non-vertically integrated competitors 14 Domestic manufacturing to benefit from newly enhanced "Buy American" rules Recurring revenue from Patient Direct expected to drive further stability and reduce risks Lexington, NC Sterilization Wrap, Isolation Gowns, Nonwoven Materials N95 Respirators Asheville, NC Minor Procedure Kits Nogales, Mexico Surgical Drapes & Packs Acuna, Mexico Face Masks, Isolation Gowns Del Rio, TX N95 Respirators Kells, Ireland Surgical Procedure Kits Williamsburg, VA Surgical Procedure Kits San Pedro Sula, Honduras Surgical Gowns Isolation Gowns Hat Yai, Thailand Exam Gloves Large, Americas-based footprint with raw materials manufactured in North Carolina provides the foundation for a fully vertically-integrated PPE manufacturing platform Owens VI & Minor#153 Vertical Integration Creates Stability and Competitive Advantage Byram APRIA- 15 |Å | DESIGN HALYARD- RAW MATERIALS MANUFACTURING ● DISTRIBUTION DISTRIBUTION Focused Vertical Approach OMI is fully vertically integrated, having manufacturing capabilities, delivery capabilities and a presence in home health 1,200+ Branded Medical Product Suppliers Vertical integration provided stability through 2020 and 2021 as PPE demand tailwinds and global supply chain disruptions were navigated Cost pass-throughs provide further flexibility and stability Significant ability to pass through costs to non-GPO customers; GPO customers have pass-throughs with some time lag DELIVERY A HOSPITAL/IDN HEALTHCARE HOME HEALTH APRIA Apria builds on OMI's end-to-end value chain Apria Enhances Breadth Apria builds on OMI's vertical integration with focus on the delivery and installation of manufactured products CHRONIC CARE AT HOME Apria also provides access to technologies and economies of scale to maintain pricing in competitive markets Many of Apria's products require respiratory technicians to set up and monitor compliance / performance in the patient's home, deepening customer relationships Technology has been a key focus as Apria has continued to invest in technology to improve operating efficiencies Owens VI & Minor#164 Diverse Earnings Profile Across Customers, Payors, Products and Geographies Combined Sales by Segment¹ Diverse End Markets 16 Patient Direct -10% $9.8 billion Product & Healthcare ~90% Owens &Minor FY 2021 Owens Services Hospital/IDN Diversification of revenue by product line and geography + $1.1 billion 100% Patient Direct APRIAⓇ FY 2021 + APRIA Limiting exposure to changes in the delivery of healthcare Byram HEALTHCARE Home health Increasing the attractiveness to payors, providers and patients -20% Patient Direct $10.9 billion Product & Healthcare -80% Owens APRIA + &Minor™ +*APRIA Byram Services Chronic care at home Fuels long-term growth 1 Combined numbers are non-GAAP and reflect the summation of OMI plus Apria, for FY 2021. See slide 2 for more information regarding OMI and Apria Combined measures and important limitations ✓ Nearly 2,000 third party payor contracts ✓ More than 1,200 supplier partners ✓ Over 4,000 healthcare industry customers ✓ Significant diversity with no single customer accounting for greater than 5% of 2021 revenue Owens VI & Minor#175 Strong Cash Flow Profile Provides Ability to Significantly Reduce Debt Financial Strength Drivers 17 ● ● ● Eliminated $700M+ of debt since Q2 2018 Improved Credit Rating from CCC+ as of December 2018 to BB- as of February 2022 After Apria acquisition, leverage ratio will be ~4x Will use same disciplined approach to reducing leverage ● Expecting to return to target leverage range of 2x-3x within 24 months Given our strong free cash flow profile, will be able to reduce debt while continuing to make appropriate investments in the business Debt and Leverage Profile* $ in millions Net Debt¹ $1,800 $1,600 $1,400 $1,200 $1,000 $800 $600 $400 $200 $0 2016 2017 2018 2019 2020 2021 8 x 7x 6x N 5x 4 x 3 x 2x 1 x Ox Leverage Ratio² *This financial information is presented on a total company basis, including continuing and discontinued operations, and is intended to reflect the most appropriate comparability of relevant metrics. ¹Reconciliations for Non-GAAP measures, including Net Debt and Total Company Adjusted EBITDA, are presented in the appendix. ²Leverage ratio = Net Debt/Adjusted EBITDA Owens VI & Minor#186 18 Highly Experienced Management with Proven Track Record of Success ED PESICKA President & Chief Executive Officer ANDY LONG EVP & Chief Financial Officer JEFF JOCHIMS EVP, Chief Operating Officer & President, Products & Healthcare Services PERRY BERNOCCHI CEO, Byram Healthcare DANIEL STARCK¹ CEO & Incoming Head, Patient Direct Years of experience 25+ 25+ 25+ 25+ 25+ Industry experience Thermo Fisher SCIENTIFIC TRW Abbott pwc patheon by Thermo Fisher Scientific Thermo Fisher SCIENTIFIC 40 MEASURES, INC. fisher scientific part of Thermo Fisher Scientific Thermo Fisher SCIENTIFIC Coram CVS specialty infusion services CAREMARK SHFM It all starts with care Hemophlia Federation of America SEARLE APRIA CORVEL Accomplishments ✓ Expanded Adj. EBITDA and margins ✓ Reduced debt levels via combination of operating cash flow, strategic divestiture, and opportunistic capital raising ✓ Enhanced liquidity profile ✓ Upgraded credit rating to BB- ✓ Improved shipping accuracy to ~99.9% ✓ Fully integrated Byram Health and Halyard acquisitions ✓ Successfully navigated shifting demands of COVID-19 pandemic ✓ Ramped up N95 respirator (1,000%+) and surgical and procedure mask (~100%) production during pandemic peak ¹Mr. Starck will join the OMI management team upon completion of Apria acquisition, which is expected to be completed in the first half of 2022. Owens VI & Minor#196 Highly Experienced Management with Proven Track Record of Success (cont'd) Byram and Halyard acquisitions have diversified the business and strengthened OMI's financial profile Target Description Strategic Rationale Impact 19 Acquired Aug 2017 Byram HEALTHCARE A leading distributor of medical supplies focused on chronic conditions sold directly to patients and home health agencies in the U.S. Diversified the Company's revenue streams across the continuum of care with a higher margin business Complemented transaction processing and developed OMI's expertise in managing third party reimbursement Operated in fragmented market with strong growth Patient Direct business has experienced significant growth since the acquisition of Byram in 2017, representing approximately a ~20% CAGR¹ since acquisition T I I I I Acquired April 2018 ✪ HALYARD D S&IP Business A leading global provider of medical supplies and solutions for the prevention of healthcare-associated infections Substantially augmented owned-brand portfolio to gain scale via targeted vertical integration Allowed company to cross-sell across existing relationships in acute and non-acute settings Expanded sourcing scale and capabilities Global Products business² has experienced significant growth since the acquisition of Halyard in 2018 - net revenue has increased from $1,434 million in 2019 to $2,656 million in 2021, representing a 36% CAGR¹,3 1 Beginning benchmark year represents the first full financial year post-acquisition; 2 Global Products includes other legacy priority products and OMI's kitting business:³ Global Products net revenue excludes impact of inter-segment revenue Owens TV & Minor#2020 Conclusion 1 6 2 5 Leading healthcare solutions company ready to drive growth through capacity and proprietary products expansion and entry into new adjacent markets 3 4 A broadening direct to patient service portfolio tailored to those with chronic conditions, builds on Byram's position as a market leader in the fast-growing home health market. Poised to continue to benefit from the "new normal" for long-term PPE requirements as a leading U.S. manufacturer Core foundation is distribution business, with 140 year history of service, support and partnership with leading healthcare providers Strategic plan focusing on investments in high-margin, growth-focused areas of the business that will help drive operating leverage and margin expansion over the long-term Building financial strength by expanding cash-generating capabilities that will help fund critical investments and further growth Owens VI & Minor#2121 CM Mwen Appendix M&Minor Owens VI & Minor#2222 OMI-2021 Summary Highlights • Delivered on our 2021 guidance • Showed strong revenue growth ● ● Growth across the entire business led by Patient Direct, Global Products and Medical Distribution ● Both PPE and S&IP sales were up year-over-year • Our vertically-integrated business model allowed us to manage macro cost pressures • Continued to capture operating leverage through our investments in expanding manufacturing capacity, utilizing technology and strengthening infrastructure • Affirmed 2022 adj. EBITDA and adj. EPS guidance, and provided 2022 revenue guidance and modeling assumptions Please see Form 8-K filed by Owens & Minor, Inc. with the SEC on February 23, 2022 for additional financial information. Owens VI & Minor#2323 OMI - 2022 Company Outlook • Revenue for 2022 expected to be in a range of $9.2 billion to $9.6 billion After normalizing our revenue for the pass through of glove cost changes, the midpoint of our 2022 revenue guidance projects 1% growth vs 2021 ● ● ● ● ● Adjusted net income for 2022 to be in a range of $3.00 to $3.50 per share Expecting near-term unfavorable commodity prices • Full year gross margin range approximately 15% Adjusted EBITDA for 2022 to be in a range of $400 million to $450 million Excludes any 2022 contribution from pending Apria acquisition Expecting PPE volumes to ease throughout the year but expect the new baseline level will be meaningfully above pre-pandemic levels; expect elective procedures at pre-pandemic levels New glove manufacturing capacity expansion go-live in late Q1'2022 ● Assumes FX rates as of December 31, 2021 Please see Form 8-K filed by Owens & Minor, Inc. with the SEC on February 23, 2022 for additional financial information. Owens VI & Minor#2424 OMI - 2022 Modeling Assumptions Revenue Gross Margin Modeling Assumptions* Interest Expense Capital Expenditures Adj. Effective Tax Rate Diluted Weighted Average Shares Outstanding Commodity Prices Expected Contribution from Apria * Full Year 2022 Please see Form 8-K filed by Owens & Minor, Inc. with the SEC on February 23, 2022 for additional financial information. $9.2 $9.6 billion -15% $42 $46 million $50 $60 million 24% -26% ~77 million Unfavorable in near-term Excluded from 2022 guidance Modeling parameters are assumptions used for 2022 adjusted EPS guidance as of the Company's Form 8-K filed on February 23, 2022. Owens VI & Minor#2525 * Glove Cost Pass-Through (GCPT) Effect on Full-Year Revenue Revenue GCPT Price Impact Revenue (ex. GCPT) 2020 $8.5 billion N/A $8.5 billion 2021 $9.8 billion. $660 million $9.1 billion 2022 Guidance* $9.4 billion $235 million $9.2 billion ¹22 vs '21 $ Variance $(0.4) billion $(425) million $0.1 billion. Please see Form 8-K filed by Owens & Minor, Inc. with the SEC on February 23, 2022 for additional financial information. '22 vs '21 % Variance (4)% (64)% 1% Uses the mid-point of our full-year 2022 guidance ranges. We estimate FY22 revenue will be reduced by $(400) - $(450) million vs FY21 as glove costs normalize. Owens VI & Minor#2626 Use of Non-GAAP Measures This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). In general, the measures exclude items and charges that (i) management does not believe reflect Owens & Minor, Inc.'s (the "Company") core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends. Management uses these non-GAAP financial measures internally to evaluate the Company's performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation. Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company's performance to that of its competitors. However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated. Owens VI & Minor#2727 Total Company Adjusted EBITDA Reconciliation $ in millions Adjusted EBITDA (Adj. EBITDA) Reconciliation Net income (loss), as reported (GAAP) Loss from discontinued operations, net of tax Income tax provision (benefit) Interest expense, net Intangible amortization Other depreciation and amortization EBITDA (non-GAAP) Acquisition-related and exit and realignment charges Loss on extinguishment and modification of debt Goodwill and intangible asset impairment charges Fair value adjustments related to purchase accounting Other expense (income), net Software as a service implementation costs and other Adjusted EBITDA (Adj. EBITDA) Certain totals in this appendix may not sum due to rounding $ $ $ YTD 2021 221.6 55.2 48.1 39.8 50.8 415.5 34.1 40.4 2.3 $ $ 492.3 $ YTD 2020 29.9 $ 58.2 21.8 83.4 41.5 51.8 286.6 37.8 11.2 (0.4) 335.2 YTD 2019 (62.4) $ (437.0) $ 39.8 (6.1) 98.1 44.0 72.7 $ 186.1 30.1 0.8 4.4 $ 221.4 $ YTD 2018 $ (32.2) 77.0 36.5 65.4 (290.2) $ 62.2 439.6 27.1 3.5 242.2 YTD 2017 72.8 (15.3) 31.8 16.4 43.0 148.7 60.7 13.4 $ 222.8 $ $ $ YTD 2016 108.8 63.8 27.1 10.0 45.4 255.0 24.7 279.7 Owens VI & Minor#2828 Total Company Net Debt Reconciliation $ in millions Net Debt Reconciliation Total Company Debt, as reported (GAAP) Cash and cash equivalents Net Debt Certain totals in this appendix may not sum due to rounding YTD 2021 YTD 2020 YTD 2019 949.6 $ 1,026.0 $ 1,563.8 $ (55.7) (83.1) 893.9 $ 942.9 $ (68.4) 1,495.4 $ YTD 2018 1,681.2 $ (103.4) 1,577.8 $ YTD 2017 917.4 $ (104.5) 812.8 $ YTD 2016 569.4 (185.5) 383.9 Owens VI & Minor#29Combined Adjusted EBITDA Reconciliation 29 $ in millions Combined Adjusted EBITDA Reconciliation Net income (loss), as reported (GAAP) Income tax provision (benefit) Interest expense, net Loss from equity method investment Depreciation and amortization EBITDA (non-GAAP) Acquisition-related and exit and realignment charges Loss on extinguishment and modification of debt Legal Settlements Stock-based compensation one-time award at IPO Offering costs Other expense (income), net Other Adjusted EBITDA (Adj. EBITDA) * Historical Owens & Minor, Inc. SA 221.6 55.2 48.1 90.6 415.5 34.1 40.4 2.3 Year Ended December 31, 2021 492.3 Historical Apria, Inc.* 64.9 24.2 7.5 0.8 115.0 212.4 3.3 - 1.8 4.1 4.4 6.0 232.0 LA SA Certain totals in this appendix may not sum due to rounding Amounts and related definitions were derived from the non-GAAP financial information included within Apria's Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC. Combined 286.5 79.3 55.6 0.8 205.7 627.9 37.4 40.4 1.8 4.1 4.4 2.3 6.0 724.3 Owens VI & Minor#30Definitions of Non-GAAP Reconciliation items The following items have been excluded in our non-GAAP financial measures: Intangible amortization: Includes amortization of intangible assets established during purchase accounting for business combinations. These amounts are highly dependent on the size and frequency of acquisitions and are being excluded to allow for a more consistent comparison with forecasted, current and historical results and the results of our peers. Goodwill and intangible asset impairment charges: These charges were incurred as a result of a decline in market capitalization of the company and lower than projected financial results of certain reporting units due to customer losses and operational inefficiencies. Fair value adjustments related to purchase accounting: Includes an incremental charge to cost of goods sold from purchase accounting impacts related to the sale of acquired inventory that was written up to fair value in connection with the Halyard acquisition. Acquisition-related and exit and realignment charges: Acquisition-related charges consist primarily of transition costs for the Halyard and Byram acquisitions, as well costs associated with the pending Apria acquisition. Exit and realignment charges consist primarily of an increase in reserves associated with certain retained assets of Fusion5, wind-down costs related to Fusion5, IT restructuring charges, post closing costs associated with the Movianto divestiture, and other costs related to the reorganization of the U.S. commercial, operations and executive teams. Apria exit and realignment charges consist primarily of costs associated with the implementation of a new financial system and one-time costs associated with moving the Apria corporate headquarters. Loss on extinguishment and modification of debt: Includes the write-off of deferred financing costs and third-party fees and amounts reclassified from accumulated other comprehensive loss as a result of the termination of our interest rate swaps. Software as a service implementation costs: These charges are associated with significant global IT platforms in connection with the redesign of our global information system strategy. Other expense (income), net: Includes interest costs and net actuarial losses related to our retirement plans. Tax Adjustments: Includes a tax adjustment associated with the estimated benefits under the Tax Cuts and Jobs Act and the Coronavirus Aid, Relief, and Economic Security (CARES) Act. Other depreciation and amortization: Includes depreciation expense for property and equipment and amortization for capitalized computer software. Legal Settlements: Apria legal settlements represent the final settlement amount of a claim brought under the Private Attorneys General Act of California. Stock-based compensation one-time award at IPO: Represents expense associated with a one-time restricted stock unit ("RSUS") grant to Apria's Chief Financial Officer ("CFO") in connection with Apria's initial public offering. Offering Costs: Apria offering costs represent one-time costs relating to public offerings. As Apria did not receive any proceeds from the offerings, these costs were expensed as incurred in selling, distribution and administrative expenses in Apria's historical condensed consolidated statements of income. Other: Includes Apria's stock-based compensation, consistent with Apria's historical presentation of Adjusted EBITDA. 30 Owens VI & Minor